US12329751 — Topical roflumilast formulation having antifungal properties
Method of Use · Assigned to Arcutis Biotherapeutics Inc · Expires 2041-12-03 · 16y remaining
What this patent protects
This patent protects a method of treating fungal infections by topically administering an effective amount of roflumilast.
USPTO Abstract
The present invention is directed to a method of treating a fungal infection comprising administering topically, to a subject in need thereof, an anti-fungal effective amount of roflumilast. Preferably, topically administered roflumilast is used to treat fungal infections, fungal growth of and/or hypersensitivity to the fungi Malassezia spp. Patients may also be suffering from seborrheic dermatitis, dandruff, dupilumab facial redness, Tinea versicolor, Pityriasis versicolor, Tinea circinata, Tinea pedis, Tinea unguium, Tinea manus, Tinea cruris, Tinea corporis, Tinea faciei, Tinea capitis , and/or Tinea incognito . Topically administered roflumilast is a quick and effective antifungal agent and presents a viable alternative to current antifungal treatments.
Drugs covered by this patent
- Daliresp (ROFLUMILAST) · Arcutis
FDA Patent Use Codes
When a patent is method-of-use, FDA lists it once per applicable indication ("U-code"). Each U-code carves out a specific therapeutic use that generic filers must either license or design around.
| Code | Description | Drug |
|---|---|---|
U-3773 |
— | Daliresp |
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.